Reports Q1 revenue $177.4M, consensus $173.34M. “Pacira (PCRX) entered 2026 with strong momentum as our 5×30 strategy continues to generate clear and measurable results,” said Frank D. Lee, chief executive officer of Pacira BioSciences. “In the first quarter, we delivered solid topline performance, highlighted by renewed growth across our commercial portfolio. This performance is fueled by a powerful combination of expanding market access, growing awareness and adoption, and mounting real world evidence, all of which are reinforcing each other.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- PCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Exparel’s Proven Clinical and Economic Value Underpins Buy Rating and $38 Price Target on Pacira BioSciences
- Pacira real-world data clearer in hip arthroplasty, says H.C. Wainwright
- Pacira presents data showing lower healthcare costs for Exparel
- Pacira price target lowered to $25 from $27 at Barclays